Mereo BioPharma to Join Fireside Chat at Jefferies Healthcare Conference

LONDON, May 30, 2024 – Mereo BioPharma Group plc (NASDAQ: MREO), a biopharmaceutical firm specializing in rare diseases, announced that its CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 11:00am ET / 04:00pm BST. The event will be accessible via a live audio webcast on the Company’s website, with a replay available for two weeks.

Mereo BioPharma focuses on creating innovative treatments for rare diseases. The company has two primary rare disease product candidates: setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Ultragenyx Pharmaceutical, Inc., a partner of Mereo, has recently completed patient enrollment for a Phase 3 portion of a pivotal Phase 2/3 pediatric study of setrusumab in young adults (ages 5 to 25 years) and expects results from a Phase 3 study in pediatric patients (ages 2 to <7 years) in the first half of 2024. Ultragenyx has agreed to potential milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo retains EU and UK commercial rights and will pay royalties to Ultragenyx on sales in these regions.

Setrusumab has received orphan designation from both the EMA and FDA for osteogenesis imperfecta. It has also been granted PRIME designation by the EMA and pediatric disease designation by the FDA. Alvelestat has earned Orphan Drug Designation and Fast Track designation from the FDA for treating AATD. The company plans to launch a Phase 3 pivotal study for alvelestat in AATD-lung disease, aiming for full approval in the U.S. and Europe.

Beyond its rare disease initiatives, Mereo has two oncology candidates under clinical development. Etigilimab (anti-TIGIT) completed a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an anti-PD-1 across various tumors, including three rare tumors and gynecological cancers such as cervical, ovarian, and endometrial cancer. It is currently undergoing an investigator-led Phase 1b/2 study at MD Anderson Cancer Center in clear cell ovarian cancer.

The company’s second oncology candidate, navicixizumab, for late-stage ovarian cancer, completed a Phase 1 study and has partnered with Feng Biosciences Inc. through a global licensing agreement involving milestone payments and royalties. Mereo has also entered into an exclusive global license agreement with ReproNovo SA for the development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor. ReproNovo, a reproductive medicine firm, will handle all future development and commercialization of leflutrozole.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!